Craneware plc

Fiscal 2024 revenue increased 9% to $189.3 million. Adjusted EBITDA rose 6% to $58.3 million, with a 31% EBITDA margin, and adjusted EPS increased 9%. Management said gross profit margin stayed in the mid-80% range and operating cash conversion was 90%. ARR ended at $172 million, and debt was reduced 58% to $35.4 million, with GBP 34 million of cash on the balance sheet. Looking ahead, management did not give formal next-quarter or full-year numeric guidance, but said it expects ARR growth to become more in line with revenue growth over time, platform revenue to scale meaningfully, and overall growth to continue trending back toward double digits.

Keith Neilson framed the business as a long-term hospital software platform focused on financial and operational efficiency rather than clinical care. He emphasized a large white-space opportunity, saying the current customer base could support a revenue run rate roughly 7.5x current revenue if all potential products were sold into it. His tone was confident and strategic, with repeated emphasis on a favorable hospital backdrop, bipartisan support for value improvement in U.S. health care, and continued investment in innovation and partnerships such as Microsoft and Oracle.

Craig Preston highlighted a year of disciplined execution: revenue up 9% to $189.3 million, adjusted EBITDA up 6% to $58.3 million, adjusted EPS up 9%, and operating cash conversion at 90%. He said the company delivered a 31% EBITDA margin, maintained mid-80% gross margins, and cut debt 58% to $35.4 million, while net interest expense fell by over $2 million after paying down borrowings. He also noted capitalized R&D of $15.8 million, GBP 34 million of cash, a £5 million share buyback completed over two years, a $12.8 million dividend payment, and a final dividend of 16p per share for a total dividend of 29p.

Analysts asked about the election impact, and management said it would not speculate politically but believes hospitals are likely to face a relatively stable policy environment over the next four years, with both parties focused on improving health-care value. On sales mix, Keith Neilson said new sales should still be about 20% brand new and 80% expansion sales next year, while platform revenue is expected to grow but is not yet formally guided. In a follow-up on margin, management said platform revenue should eventually improve margins through operating leverage, but for now the priority is reinvesting to grow the total addressable market and accelerate the business. On sales cycles, management said they have shortened, helped by existing customer relationships and the ability to demonstrate value faster using the data platform.